Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents

References

• Giannini D, Antonucci M, Petrelli F, Bilia S, Alunno A, Puxeddu I. One year in review 2020: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(3):387–397.
   PubMed Web of Science ®Google Scholar
• Hanan A, Walaa G, Ahmed M, et al. Investigating the balance between Th17/Treg cells in rheumatoid arthritis and its association with disease activity. J Child Sci. 2019;09(1):e75–e83. doi:10.1055/s-0039-1693158
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123. doi:10.1002/art.41752
   PubMed Web of Science ®Google Scholar
• Selmi C, De Santis M, Gershwin ME. Liver involvement in subjects with rheumatic disease. Arthritis Res Ther. 2011;13(3):226. doi:10.1186/ar3319
   PubMed Web of Science ®Google Scholar
• García-González CM, Baker J. Treatment of early rheumatoid arthritis: methotrexate and beyond. Curr Opin Pharmacol. 2022;64:102227. doi:10.1016/j.coph.2022.102227
   Web of Science ®Google Scholar
• van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf. 2004;27(5):345–352. doi:10.2165/00002018-200427050-00006
   PubMed Web of Science ®Google Scholar
• Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69(1):43–47. doi:10.1136/ard.2008.101378
   PubMed Web of Science ®Google Scholar
• Nazir AM, Koganti B, Gupta K, et al. Evaluating the use of hydroxychloroquine in treating patients with rheumatoid arthritis. Cureus. 2021;13(11):e19308. doi:10.7759/cureus.19308
   Web of Science ®Google Scholar
• Radner H, Aletaha D. Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr. 2015;165(1–2):3–9. doi:10.1007/s10354-015-0344-y
   PubMed Web of Science ®Google Scholar
• Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–564.e3. doi:10.1016/j.cgh.2012.12.025
   PubMed Web of Science ®Google Scholar
• Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(9):1612–1617. doi:10.1136/ard.2009.112136
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459–466. doi:10.1016/S0140-6736(09)60944-2
   Web of Science ®Google Scholar
• Kluger N, Girard C, Guillot B, Bessis D. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis. Acta Derm Venereol. 2009;89(3):332–334. doi:10.2340/00015555-0619
   Web of Science ®Google Scholar
• Zhao S, Mysler E, Moots RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018;10(6):433–445. doi:10.2217/imt-2017-0155
   PubMed Web of Science ®Google Scholar
• Chen DY, Lin CH, Chen HH, Tang KT. Association of tumor necrosis factor-α inhibitors and liver cirrhosis in patients with rheumatoid arthritis: a nationwide population-based nested case-control study. Int J Rheum Dis. 2022;25(3):327–334. doi:10.1111/1756-185X.14272
   Web of Science ®Google Scholar
• Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology. 2011;50(9):1700–1711. doi:10.1093/rheumatology/ker190
   PubMed Web of Science ®Google Scholar
• Zhao S, Chadwick L, Mysler E, Moots RJ. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(10):57. doi:10.1007/s11926-018-0769-6
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563–2571.
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516. doi:10.1136/ard.2003.013052
   PubMed Web of Science ®Google Scholar
• Hartmann U, Schmitt S, Reuss-Borst M. Leberwerterhöhung bei rheumatoider Arthritis: differenzialdiagnostische Uberlegungen an einem Fallbeispiel [Elevated liver enzymes in rheumatoid arthritis: differential diagnostic considerations based on a case report]. Z Rheumatol. 2008;67(5):440–444. doi:10.1007/s00393-008-0288-3
   Google Scholar
• Lopetuso LR, Mocci G, Marzo M, et al. Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver. Int J Mol Sci. 2018;19(8):2199. doi:10.3390/ijms19082199
   Web of Science ®Google Scholar
• Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31(11):1853–1859. doi:10.1111/jdv.14146
   PubMed Web of Science ®Google Scholar
• Pelechas E, Voulgari PV, Drosos AA. Golimumab for rheumatoid arthritis. J Clin Med. 2019;8(3):387. doi:10.3390/jcm8030387
   PubMed Web of Science ®Google Scholar
• Kanbori M, Suzuka H, Yajima T, et al. Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2018;28(1):66–75. doi:10.1080/14397595.2017.1325058
   PubMed Web of Science ®Google Scholar
• Antagonists, Tumor Necrosis Factor. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Nanau RM, Neuman MG. Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci. 2014;17(3):324–361. doi:10.18433/J3WP4F
   Web of Science ®Google Scholar
• Magyari L, Varszegi D, Kovesdi E, et al. Interleukins and interleukin receptors in rheumatoid arthritis: research, diagnostics and clinical implications. World J Orthop. 2014;5(4):516–536. doi:10.5312/wjo.v5.i4.516
   PubMedGoogle Scholar
• Fardellone P, Salawati E, Le Monnier L, Goëb V. Bone loss, osteoporosis, and fractures in patients with rheumatoid arthritis: a review. J Clin Med. 2020;9(10):3361. doi:10.3390/jcm9103361
   Web of Science ®Google Scholar
• Azizi G, Jadidi-Niaragh F, Mirshafiey A. Th17 cells in immunopathogenesis and treatment of rheumatoid arthritis. Int J Rheum Dis. 2013;16(3):243–253. doi:10.1111/1756-185X.12132
   PubMed Web of Science ®Google Scholar
• Abbasi M, Mousavi MJ, Jamalzehi S, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;234(7):10018–10031. doi:10.1002/jcp.27860
   PubMed Web of Science ®Google Scholar
• Bedaiwi MK, Almaghlouth I, Omair MA. Effectiveness and adverse effects of anakinra in treatment of rheumatoid arthritis: a systematic review. Eur Rev Med Pharmacol Sci. 2021;25(24):7833–7839. doi:10.26355/eurrev_202112_27630
   Web of Science ®Google Scholar
• den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2006;65(6):760–762. doi:10.1136/ard.2004.033662
   Web of Science ®Google Scholar
• Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63(9):1062–1068. doi:10.1136/ard.2003.016014
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E. Interleukin-6 in Rheumatoid Arthritis. Int J Mol Sci. 2020;21(15):5238. doi:10.3390/ijms21155238
   Web of Science ®Google Scholar
• Li Y, Zhang W. IL-6: TNF-α 之后的类风湿关节炎治疗关键靶点 [IL-6: the next key target for rheumatoid arthritis after TNF-α]. Sheng Wu Gong Cheng Xue Bao. 2017;33(1):36–43. Chinese. doi:10.13345/j.cjb.160241
   Google Scholar
• Scott LJ. Tocilizumab: a Review in Rheumatoid Arthritis. Drugs. 2017;77(17):1865–1879. doi:10.1007/s40265-017-0829-7
   PubMed Web of Science ®Google Scholar
• Baek HJ, Lim MJ, Park W, et al. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. Korean J Intern Med. 2019;34(4):917–931. doi:10.3904/kjim.2017.159
   PubMed Web of Science ®Google Scholar
• Amouzougan A, Dénarié D, Marotte H, Roblin X, Thomas T. Rheumatoid arthritis treated with tocilizumab in two patients with complicated chronic liver disease with portal hypertension. Joint Bone Spine. 2018;85(1):115–117. doi:10.1016/j.jbspin.2017.07.004
   Web of Science ®Google Scholar
• Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018. Expert Rev Clin Immunol. 2018;14(7):539–547. doi:10.1080/1744666X.2018.1487291
   PubMed Web of Science ®Google Scholar
• Lazzerini PE, Capecchi PL, Guidelli GM, Selvi E, Acampa M, Laghi-Pasini F. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Devel Ther. 2016;10:3083–3098. doi:10.2147/DDDT.S99898
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Harigai M, et al. Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Mod Rheumatol. 2019;29(2):306–313. doi:10.1080/14397595.2018.1452345
   PubMed Web of Science ®Google Scholar
• Moura RA, Fonseca JE. JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis. Front Med. 2021;7:607725. doi:10.3389/fmed.2020.607725
   Web of Science ®Google Scholar
• Keystone EC, Cohen SB, Emery P, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol. 2012;39(12):2238–2246. doi:10.3899/jrheum.120573
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–1502. doi:10.1136/annrheumdis-2012-201956
   PubMed Web of Science ®Google Scholar
• Kaegi C, Steiner UC, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders. Allergy. 2021;76(9):2673–2683. doi:10.1111/all.14704
   Web of Science ®Google Scholar
• Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a Phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013;40(5):579–589. doi:10.3899/jrheum.120886
   PubMed Web of Science ®Google Scholar
• Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist. 2018;23(9):991–997. doi:10.1634/theoncologist.2018-0174
   PubMed Web of Science ®Google Scholar
• Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965–973. doi:10.1038/s41379-018-0013-y
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang X, Geng X, et al. Risk of hepatitis B virus reactivation following treatment with Abatacept: a retrospective study of international pharmacovigilance databases. EClinicalMedicine. 2022;48:101425. doi:10.1016/j.eclinm.2022.101425
   PubMedGoogle Scholar
• Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64(6):1790–1798. doi:10.1002/art.34329
   PubMed Web of Science ®Google Scholar
• Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. 2020;43(4):148–155. doi:10.1080/25785826.2020.1770948
   PubMedGoogle Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or Adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519. doi:10.1056/NEJMoa1112072
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662. doi:10.1056/NEJMoa1608345
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252. doi:10.1056/NEJMoa1507247
   PubMed Web of Science ®Google Scholar
• Lopez-Romero P, de la Torre I, Haladyj E, Aletaha D, Smolen JS. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2022;81(5):622–631. doi:10.1136/annrheumdis-2021-221323
   Web of Science ®Google Scholar
• Clarke B, Yates M, Adas M, Bechman K, Galloway J. The safety of JAK-1 inhibitors. Rheumatology. 2021;60(Suppl2):ii24–ii30. doi:10.1093/rheumatology/keaa895
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Westhovens RR, Winthrop KL, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of Phase II rheumatoid arthritis programs. J Rheumatol. 2021;48(8):1230–1238. doi:10.3899/jrheum.201183
   PubMed Web of Science ®Google Scholar
• Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404–1419. doi:10.1016/j.mayocp.2020.01.039
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511–1521. doi:10.1056/NEJMoa2008250
   PubMed Web of Science ®Google Scholar
• Trueman S, Mohamed MF, Feng T, Lacerda AP, Marbury T, Othman AA. Characterization of the effect of hepatic impairment on upadacitinib pharmacokinetics. J Clin Pharmacol. 2019;59(9):1188–1194. doi:10.1002/jcph.1414
   PubMed Web of Science ®Google Scholar
• Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol. 2021;36(8):2091–2100. doi:10.1111/jgh.15399
   Web of Science ®Google Scholar